NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
